Saudi Arabia Emerges as a Global Biotech Investment Hub Under Vision 2030

Senior Saudi Government, Investment and Healthcare Leaders to Attend the CEL-SCI / Amarox Signing & Opening Ceremonies

Strategic Agreement Marks Important Step Toward Commercialization of Multikine® in One of the Middle East's Fastest-Growing Healthcare Markets

CEL-SCI Corporation (NYSE:CVM) today announced it will participate in a formal signing ceremony with Saudi Amarox ("Amarox") during the BIO International Convention 2026 in San Diego, California. The ceremony will mark an important milestone in advancing the previously announced strategic agreement between the companies focused on the commercialization and distribution of Multikine®* (Leukocyte Interleukin, Injection) in the Kingdom of Saudi Arabia.

The BIO International Convention, the world's largest biotechnology industry event, will take place June 22-25, 2026, bringing together biotechnology, pharmaceutical, investment and government leaders from around the world.

The official signing ceremony will take place during the opening ceremony of the Saudi Amarox booth on Monday, June 22, 2026, from 12:00 PM to 1:00 PM PST. CEL-SCI's Chief Executive Officer Geert Kersten and representatives from Amarox will participate in the ceremony, formally recognizing the companies' collaboration on bringing Multikine to patients in Saudi Arabia.

The event comes as Saudi Arabia accelerates its emergence as a global leader in biotechnology and life sciences investments under the Kingdom's Vision 2030 strategy. The Saudi Ministry of Health is an official sponsor of BIO 2026 and has established biotechnology as a strategic priority, with significant public and private investment.